BryoLogyx Inc. is an emerging San Francisco Bay Area biopharmaceutical company focused on becoming a major clinical and commercial innovator in cancer immunotherapy and HIV cure using the synthetic form of bryostatin-1, and potentially superior bryostatin-derived analog compounds (bryologs).
The bryostatin technology, across both oncology and HIV, is based on bryostatin’s ability to activate, and sensitize, cells resulting heightened immune recognition, and clearance by immunotherapeutic agents, and innate host immune mechanisms. In cancer, this innovative approach will improve performance of immuno-oncology agents such as chimeric antigen receptor T-cells (CAR-T), immune checkpoint inhibitors and monoclonal antibodies. In HIV, bryostatin will provide activation of the latent reservoir as part of the “kick and kill” cure paradigm. BryoLogyx will secure its exclusive worldwide license from Stanford University in January 2018. This license, which will cover therapeutic applications in cancer and HIV, is based on the synthesis of bryostatin-1 and related bryolog compounds, created by the Wender Group at Stanford University.